A thermoresponsive hydrogel system for long-acting corticosteroid delivery into the paranasal sinuses

被引:20
|
作者
Schilling, Andrea L. [1 ]
Kulahci, Yalcin [1 ]
Moore, John [2 ]
Wang, Eric W. [2 ]
Lee, Stella E. [2 ]
Little, Steven R. [1 ,3 ,4 ,5 ,6 ,7 ]
机构
[1] Univ Pittsburgh, Dept Chem Engn, 940 Benedum Hall,3700 OHara St, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, 1400 Locust St,Suite 2100, Pittsburgh, PA 15219 USA
[3] Univ Pittsburgh, Dept Bioengn, 302 Benedum Hall,3700 OHara St, Pittsburgh, PA 15213 USA
[4] Univ Pittsburgh, Dept Clin & Translat Sci, Forbes Tower,Suite 7057, Pittsburgh, PA 15213 USA
[5] Univ Pittsburgh, McGowan Inst Regenerat Med, 450 Technol Dr,Suite 300, Pittsburgh, PA 15219 USA
[6] Univ Pittsburgh, Dept Immunol, 200 Lothrop St, Pittsburgh, PA 15213 USA
[7] Univ Pittsburgh, Dept Pharmaceut Sci, 3501 Terrace St, Pittsburgh, PA 15213 USA
基金
美国国家卫生研究院;
关键词
Thermoresponsive; Microsphere; Hydrogel; Sustained release; Steroid; Sinusitis;
D O I
10.1016/j.jconrel.2020.10.062
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Delivering localized treatment to the paranasal sinuses for diseases such as chronic rhinosinusitis (CRS) is particularly challenging because of the small natural openings leading from the sinuses that can be further obstructed by presence of inflammation. As such, oral steroids, topical nasal sprays or irrigation, and surgery can be utilized to treat persistent sinonasal inflammation, but there exists a need for post-operative options for long-term steroid delivery to prevent disease recurrence. In the present study, a Thermogel, Extended-release Microsphere-based-delivery to the Paranasal Sinuses (TEMPS) is developed with the corticosteroid mometasone furoate. Specifically, the bioactive steroid is released for 4 weeks from poly(lactic-co-glycolic acid) (PLGA) microspheres embedded in a poly(N-isopropylacrylamide) (p-NIPAAm)-based hydrogel. The temperature-responsive system undergoes a reversible sol-gel transition at 34-35 degrees C such that it can be applied as a liquid at ambient temperature, conforming to the sinonasal epithelium as it gels. In a rabbit model of CRS, TEMPS was maintained in rabbit sinuses and effectively reduced sinonasal inflammation as characterized by micro-computed tomography and histopathology analysis. Ultimately, the combination of controlled release microspheres with a thermoresponsive hydrogel provides flexibility for encapsulating therapeutics in a reversible and conforming system for localized delivery to the sinuses.
引用
收藏
页码:889 / 897
页数:9
相关论文
共 50 条
  • [21] Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis
    Oba, Yuji
    Chandran, Arul V.
    Devasahayam, Joe V.
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 13 (06) : 677 - 685
  • [22] Design of a Long-Acting Rivastigmine Transdermal Delivery System: Based on Computational Simulation
    Xue Han
    Jingchuan Liu
    Xiaoyue Hu
    Wei Wang
    Qing Wang
    AAPS PharmSciTech, 23
  • [23] Design of a Long-Acting Rivastigmine Transdermal Delivery System: Based on Computational Simulation
    Han, Xue
    Liu, Jingchuan
    Hu, Xiaoyue
    Wang, Wei
    Wang, Qing
    AAPS PHARMSCITECH, 2022, 23 (01)
  • [24] Long-acting muscarinic antagonist plus long-acting beta agonist versus long-acting beta agonist plus inhaled corticosteroid for COPD: A systematic review and meta-analysis
    Horita, Nobuyuki
    Miyazawa, Naoki
    Tomaru, Koji
    Inoue, Miyo
    Kaneko, Takeshi
    RESPIROLOGY, 2015, 20 (08) : 1153 - 1159
  • [25] New long acting topically applied treatments with bioadhesive hydrogel delivery system
    Shah, K.
    Vlahovic, T.
    Mills, O.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 : S38 - S38
  • [26] Bronchoprotective tolerance with inhaled corticosteroid/long-acting β-agonist treatment Reply
    Cardet, Juan Carlos
    Jiang, Xiaofeng
    Lu, Quan
    Gerard, Norma
    McIntire, Kristen
    Boushey, Homer A.
    Castro, Mario
    Chinchilli, Vernon M.
    Codispoti, Christopher D.
    Dyer, Anne-Marie
    Holguin, Fernando
    Kraft, Monica
    Lazarus, Stephen
    Lemanske, Robert F.
    Lugogo, Njira
    Mauger, Dave
    Moore, Wendy C.
    Moy, James
    Ortega, Victor E.
    Peters, Stephen P.
    Smith, Lewis J.
    Solway, Julian
    Sorkness, Christine A.
    Sumino, Kaharu
    Wechsler, Michael E.
    Wenzel, Sally
    Israel, Elliot
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 144 (03) : 873 - 874
  • [27] FIELD TRIALS OF A NEW LONG-ACTING CORTICOSTEROID IN TREATMENT OF EQUINE ARTHROPATHIES
    HOUDESHELL, JW
    VETERINARY MEDICINE & SMALL ANIMAL CLINICIAN, 1969, 64 (09): : 782 - +
  • [28] TREATMENT OF DERMATOSES BY INTRAMUSCULAR INJECTION OF A LONG-ACTING CORTICOSTEROID, TRIAMCINOLONE ACETONIDE
    OLANSKY, S
    MCCORMICK, GEA
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1963, 5 (06): : 319 - &
  • [29] Clinical translation of long-acting drug delivery formulations
    Wei Li
    Jie Tang
    Dennis Lee
    Thomas R. Tice
    Steven P. Schwendeman
    Mark R. Prausnitz
    Nature Reviews Materials, 2022, 7 : 406 - 420
  • [30] Long-acting therapeutic delivery systems for the treatment of gliomas
    Padmakumar, Smrithi
    Amiji, Mansoor M.
    ADVANCED DRUG DELIVERY REVIEWS, 2023, 197